AbbVie Inc. (NEO:ABBV)

Market Cap	470.12B
Revenue (ttm)	82.46B
Net Income (ttm)	5.97B
Shares Out	n/a
EPS (ttm)	3.36
PE Ratio	78.72
Forward PE	14.90
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,396
Average Volume	10,728,393
Open	26.75
Previous Close	26.44
Day's Range	26.75 - 27.52
52-Week Range	22.44 - 31.45
Beta	0.54
RSI	52.57
Earnings Date	Apr 25, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Cboe Canada
• Ticker Symbol: ABBV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD